secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001564590-21-056451
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q3 2021 net loss $39.5M for nine months; cash $326.3M
----------------------------------------------------------------

- Net loss for nine months ended Sep 30, 2021: $39.5M vs $24.0M in prior-year period.
- Cash, equivalents and marketable securities: $326.3M as of Sep 30, 2021; sufficient through end of 2023.
- R&D expenses increased to $24.3M (from $17.8M) driven by PC14586 clinical development.
- Phase 1/2 trial of p53 Y220C reactivator PC14586 data expected in first half 2022.
- Appointed Tim Smith as SVP, Head of Corporate Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000156459021056451/0001564590-21-056451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000156459021056451/pmvp-8k_20211112.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer